US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Insight Molecular Diagnostics Inc.

3.56

-0.5500-13.38%

Post-market: 3.800.2403+6.75%18:10 EDT

Volume:341.80K

Turnover:1.26M

Market Cap:114.44M

PE:-1.26

High:4.37

Open:4.17

Low:3.29

Close:4.11

52wk High:8.51

52wk Low:2.33

Shares:32.15M

Float Shares:11.26M

Volume Ratio:1.59

T/O Rate:3.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8272

EPS(LYR):-4.6612

ROE:-23603.11%

ROA:-28.44%

PB:-12.44

PE(LYR):-0.76

Loading ...

Overview Company News Filings

Insight Molecular Diagnostics signs specimen collection agreement with Quest Diagnostics

Insight Molecular Diagn Is Maintained at Buy by Lake Street

Broadwood Partners Reports Acquisition of Insight Molecular Diagnostics Inc. Common Shares

BRIEF-Imdx Announces $26.0 Million Registered Direct Offering

Insight Molecular Diagnostics Raises $26 Million in Registered Direct Offering of Shares and Pre-Funded Warrants

Insight Molecular Diagnostics Unveils Decentralized dd-cfDNA Test for Transplant Monitoring

Insight Molecular Diagnostics Inc. Joins JPM Week and BTIG Snowbird Investor Conferences

Insight Molecular Diagnostics Appoints Dr. Nick Ioannou as Vice President of Medical Affairs

Press Release: iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Imdx Prepares for U.S. Commercial Launch of Graftassuredx as Clinical Trial Nears Completion

THOMSON REUTERS

Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11%

Simply Wall St.

Insight Molecular Diagnostics Reaffirms Mid-2026 Launch Plans

Insight Molecular Diagnostics Inc. reports $260,000 Q3 2025 revenue from laboratory services

Insight Molecular Diagnostics Inc - Q3 2025 Net Loss $10.9 Mln, or $-0.34 per Share

THOMSON REUTERS

Insight Molecular Diagnostics Inc - Graftassuredx to Be Submitted for FDA Review by Year-End

THOMSON REUTERS

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Insight Molecular Diagnostics Inc expected to post a loss of 21 cents a share - Earnings Preview

BRIEF-Imdx Welcomes New VP Marketing To Prepare For Commercial Transplant Assay Launch

Imdx Welcomes New Vp Marketing to Prepare for Commercial Transplant Assay Launch

THOMSON REUTERS

Press Release: iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMDX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","market":"US","secType":"STK","nameCN":"Insight Molecular Diagnostics Inc.","latestPrice":3.56,"timestamp":1774641600000,"preClose":4.11,"halted":0,"volume":341804,"hourTrading":{"tag":"盘后","latestPrice":3.8003,"preClose":3.56,"latestTime":"18:10 EDT","volume":1347,"amount":5075.8459,"timestamp":1774649431875,"change":0.2403,"changeRate":0.0675,"amplitude":0.11236},"delay":0,"changeRate":-0.13381995133819957,"floatShares":11264900,"shares":32146900,"eps":-2.8272,"marketStatus":"Closed","change":-0.55,"latestTime":"03-27 16:00:00 EDT","open":4.17,"high":4.37,"low":3.291,"amount":1256332.2872308001,"amplitude":0.26253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.8272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":4.11,"preHourTrading":{"tag":"盘前","latestPrice":3.85,"preClose":4.11,"latestTime":"09:29 EDT","volume":2515,"amount":10049.693027,"timestamp":1774618164746,"change":-0.26,"changeRate":-0.06326,"amplitude":0.13382},"postHourTrading":{"tag":"盘后","latestPrice":3.8003,"preClose":3.56,"latestTime":"18:10 EDT","volume":1347,"amount":5075.8459,"timestamp":1774649431875,"change":0.2403,"changeRate":0.0675,"amplitude":0.11236},"volumeRatio":1.58505,"impliedVol":8.6435,"impliedVolPercentile":0.9247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","floatShares":11264900,"roa":"-28.44%","roe":"-23603.11%","lyrEps":-4.661158,"volumeRatio":1.58505,"shares":32146900,"dividePrice":0,"high":4.37,"amplitude":0.26253,"preClose":4.11,"low":3.291,"week52Low":2.33,"pbRate":"-12.44","psRate":"26.00","week52High":8.51,"institutionHeld":0,"latestPrice":3.56,"eps":-2.8272,"divideRate":0,"volume":341804,"delay":0,"ttmEps":-2.8272,"open":4.17,"prevYearClose":7.5,"prevWeekClose":4.26,"prevMonthClose":6.01,"prevQuarterClose":7.5,"fiveDayClose":4.26,"twentyDayClose":6.01,"sixtyDayClose":7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMDX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-26","symbol":"IMDX","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-11-10","symbol":"IMDX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2025-08-11","symbol":"IMDX","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-12","symbol":"IMDX","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-03-24","symbol":"IMDX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMDX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMDX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1743220800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMDX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMDX","date":"2026-03-26","current":-1.259196,"percent":0.546875,"low":-3.993147,"twenty":-3.009097,"median":-2.40278,"eighty":-1.395447,"high":-1.083107,"avg":-2.25511,"sd":0.806788,"marketCap":133169558},"quantilePoints":[{"date":"2025-06-20","current":-1.55268,"twenty":-1.55268,"median":-1.55268,"eighty":-1.55268,"marketCap":90373740},{"date":"2025-06-27","current":-1.655864,"twenty":-1.798357,"median":-1.675518,"eighty":-1.638667,"marketCap":96379590},{"date":"2025-07-03","current":-1.40036,"twenty":-1.71581,"median":-1.6055,"eighty":-1.491752,"marketCap":81507962},{"date":"2025-07-11","current":-1.420014,"twenty":-1.663726,"median":-1.493717,"eighty":-1.427876,"marketCap":82651933},{"date":"2025-07-18","current":-1.390533,"twenty":-1.642106,"median":-1.471607,"eighty":-1.399377,"marketCap":80935976},{"date":"2025-07-25","current":-1.454409,"twenty":-1.585601,"median":-1.459323,"eighty":-1.399377,"marketCap":84653883},{"date":"2025-08-01","current":-1.238213,"twenty":-1.556611,"median":-1.424927,"eighty":-1.390533,"marketCap":72070198},{"date":"2025-08-08","current":-1.289805,"twenty":-1.50551,"median":-1.405274,"eighty":-1.357121,"marketCap":75073123},{"date":"2025-08-15","current":-1.083107,"twenty":-1.489787,"median":-1.40036,"eighty":-1.288331,"marketCap":68687397},{"date":"2025-08-22","current":-1.119211,"twenty":-1.488804,"median":-1.395447,"eighty":-1.253936,"marketCap":70976977},{"date":"2025-08-29","current":-1.132749,"twenty":-1.484873,"median":-1.380706,"eighty":-1.161632,"marketCap":71835569},{"date":"2025-09-05","current":-1.114698,"twenty":-1.480942,"median":-1.363484,"eighty":-1.138165,"marketCap":70690780},{"date":"2025-09-12","current":-1.435117,"twenty":-1.467185,"median":-1.353884,"eighty":-1.132749,"marketCap":91010801},{"date":"2025-09-19","current":-1.520863,"twenty":-1.485856,"median":-1.368397,"eighty":-1.138165,"marketCap":96448554},{"date":"2025-09-26","current":-1.47122,"twenty":-1.485856,"median":-1.389987,"eighty":-1.149898,"marketCap":93300381},{"date":"2025-10-03","current":-1.507324,"twenty":-1.490769,"median":-1.392517,"eighty":-1.163437,"marketCap":95589961},{"date":"2025-10-10","current":-1.714919,"twenty":-1.500103,"median":-1.395447,"eighty":-1.171561,"marketCap":108755046},{"date":"2025-10-17","current":-2.087237,"twenty":-1.528084,"median":-1.402817,"eighty":-1.173366,"marketCap":132366339},{"date":"2025-10-24","current":-2.897311,"twenty":-1.598867,"median":-1.417558,"eighty":-1.192321,"marketCap":183738788},{"date":"2025-10-31","current":-2.67392,"twenty":-1.674528,"median":-1.432479,"eighty":-1.204957,"marketCap":169572012},{"date":"2025-11-07","current":-2.933415,"twenty":-1.775372,"median":-1.457682,"eighty":-1.224911,"marketCap":186028368},{"date":"2025-11-14","current":-3.696486,"twenty":-2.084901,"median":-1.473476,"eighty":-1.250005,"marketCap":224665029},{"date":"2025-11-21","current":-2.862765,"twenty":-2.669859,"median":-1.478977,"eighty":-1.260815,"marketCap":173993132},{"date":"2025-11-28","current":-2.895779,"twenty":-2.764631,"median":-1.48389,"eighty":-1.270643,"marketCap":175999643},{"date":"2025-12-05","current":-2.631669,"twenty":-2.764631,"median":-1.488804,"eighty":-1.282435,"marketCap":159947558},{"date":"2025-12-12","current":-2.452451,"twenty":-2.743778,"median":-1.493785,"eighty":-1.285383,"marketCap":149055072},{"date":"2025-12-19","current":-2.447735,"twenty":-2.714849,"median":-1.505068,"eighty":-1.294719,"marketCap":148768428},{"date":"2025-12-26","current":-2.744859,"twenty":-2.739199,"median":-1.51635,"eighty":-1.307003,"marketCap":166827023},{"date":"2026-01-02","current":-3.537189,"twenty":-2.766436,"median":-1.545684,"eighty":-1.326657,"marketCap":214983277},{"date":"2026-01-09","current":-3.537189,"twenty":-2.848616,"median":-1.572334,"eighty":-1.341398,"marketCap":214983277},{"date":"2026-01-16","current":-3.122159,"twenty":-2.895779,"median":-1.658314,"eighty":-1.353884,"marketCap":189758572},{"date":"2026-01-23","current":-3.150456,"twenty":-2.900495,"median":-1.677968,"eighty":-1.357494,"marketCap":191478439},{"date":"2026-01-30","current":-3.122159,"twenty":-2.986727,"median":-1.755536,"eighty":-1.360521,"marketCap":189758572},{"date":"2026-02-06","current":-3.155173,"twenty":-3.018554,"median":-1.819819,"eighty":-1.364943,"marketCap":191765083},{"date":"2026-02-13","current":-2.951395,"twenty":-3.074996,"median":-2.083343,"eighty":-1.369886,"marketCap":179379897},{"date":"2026-02-20","current":-2.87381,"twenty":-3.072166,"median":-2.244936,"eighty":-1.382344,"marketCap":174664420},{"date":"2026-02-27","current":-3.000829,"twenty":-3.054013,"median":-2.378582,"eighty":-1.390315,"marketCap":182384395},{"date":"2026-03-06","current":-2.900272,"twenty":-3.054013,"median":-2.405289,"eighty":-1.390533,"marketCap":176272748},{"date":"2026-03-13","current":-2.588017,"twenty":-3.035708,"median":-2.450093,"eighty":-1.392913,"marketCap":157294478},{"date":"2026-03-20","current":-2.074647,"twenty":-3.019142,"median":-2.42887,"eighty":-1.395068,"marketCap":126092915},{"date":"2026-03-26","current":-2.191082,"twenty":-3.009097,"median":-2.40278,"eighty":-1.395447,"marketCap":133169558}],"updateTime":1774656429992},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMDX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614079679","title":"Insight Molecular Diagnostics signs specimen collection agreement with Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079679?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:22","pubTimestamp":1772140959,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc. entered into a Specimen Collection Agreement with Quest Diagnostics Incorporated on February 20, 2026. Under the agreement, Quest will provide specimen collection-related services for specimens on which Insight will perform its GraftAssureCore test, and Insight will pay Quest fees for the services. The parties also agreed to use commercially reasonable efforts for a specified period to negotiate in good faith certain additional rights to the GraftAssure technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLwcvCr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139","BK4082","MDIT"],"gpt_icon":0},{"id":"2612163462","title":"Insight Molecular Diagn Is Maintained at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2612163462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612163462?lang=en_us&edition=fundamental","pubTime":"2026-02-18 03:52","pubTimestamp":1771357920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 14:52 ET (19:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2611326902","title":"Broadwood Partners Reports Acquisition of Insight Molecular Diagnostics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611326902","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611326902?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:50","pubTimestamp":1770943836,"startTime":"0","endTime":"0","summary":"Broadwood Partners, L.P. reported the acquisition of common shares of Insight Molecular Diagnostics Inc. Other reporting beneficial owners were also included in the filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL1bvm5c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139","BK4082","MDIT"],"gpt_icon":0},{"id":"2610095389","title":"BRIEF-Imdx Announces $26.0 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610095389","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610095389?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:50","pubTimestamp":1770817845,"startTime":"0","endTime":"0","summary":"BRIEF-Imdx Announces $26.0 Million Registered Direct OfferingFeb 11 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O:IMDX ANNOUNCES $26.0 MILLION REGISTERED DIRECT OFFERINGSource text: ID:nGNX71hLPcFurther company coverage: IMDX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA1KJXNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2610305159","title":"Insight Molecular Diagnostics Raises $26 Million in Registered Direct Offering of Shares and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2610305159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610305159?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:05","pubTimestamp":1770815136,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 4,525,976 shares of its common stock, or pre-funded warrants in lieu thereof, at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the purchase price per share of common stock, less the exercise price of $0.0001 per share. The offering is expected to result in gross proceeds of approximately $26.0 million before fees and expenses. Proceeds will support research and development, particularly the expansion of the GraftAssure product offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLSy6B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","MDIT","BK4139","BK4082"],"gpt_icon":0},{"id":"2603868719","title":"Insight Molecular Diagnostics Unveils Decentralized dd-cfDNA Test for Transplant Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2603868719","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603868719?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:00","pubTimestamp":1768312851,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc.  announced support for the STAR working group’s recent position paper in the American Journal of Transplantation, which calls for decentralized donor-derived cell-free DNA  testing in transplant monitoring. The paper highlights the importance of high-quality, standardized decentralized testing and the diagnostic value of absolute quantification of dd-cfDNA—a key feature of IMDX’s GraftAssure family of assays. IMDX’s technology, developed by its scientists in Germany and the U.S., is commercially available through its GraftAssureCore laboratory-developed test and the GraftAssureIQ research-use-only kit. The company is pursuing decentralization of transplant rejection testing, aiming to improve patient care and hospital sustainability in a growing market. The research results referenced are detailed in the recently published position paper.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1rBfRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4588","IMDX","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601389344","title":"Insight Molecular Diagnostics Inc. Joins JPM Week and BTIG Snowbird Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389344","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389344?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:05","pubTimestamp":1767819951,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc.  will participate in several investor conferences this winter. The company’s management team will hold one-on-one meetings at the LifeSci Advisors 15th Annual Corporate Access Event on January 12 in San Francisco, as well as additional investor meetings in San Francisco from January 12 to January 14 during \"JPM Week.\" iMDx will also attend the BTIG 13th Annual Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, taking place from February 9 to 11 at Cliff Lodge in Snowbird, Utah.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 07, 2026, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6fzSNp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4082","LU2095319765.USD","LU0314104364.USD","BK4588","SG9999014005.SGD","BK4139","SG9999014021.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","IMDX","NDAQ","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","MDIT"],"gpt_icon":0},{"id":"2601089765","title":"Insight Molecular Diagnostics Appoints Dr. Nick Ioannou as Vice President of Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089765","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601089765?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:01","pubTimestamp":1767704509,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc. has appointed Dr. Nick Ioannou as Vice President of Medical Affairs. Dr. Ioannou brings over thirty years of experience in clinical practice, diagnostics, and medical affairs, with a focus on organ transplantation, nephrology, cardiology, genetics, and oncology. He joins the company as it prepares to launch its first commercial transplant assay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5bNQhK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK4585","BK4139","BK4082","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","MDIT","BK4112","IMDX","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2601507897","title":"Press Release: iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2601507897","media":"Dow Jones","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601507897?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:01","pubTimestamp":1767704460,"startTime":"0","endTime":"0","summary":"-- Dr. Nick Ioannou brings decades of academia, industry, and clinical. experience in organ transplant, nephrology, cardiology, genetics, and. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeutic areas, particularly in organ transplantation, nephrology, cardiology, pulmonology, genetics, and oncology.Dr. Ioannou received a Bachelor of Science in Microbiology from California State University, Northridge, a Master of Healthcare Administration from Saint Joseph's College of Maine and completed his Medical Doctorate clinical training at Michael Reese Hospital in Chic","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4604","BK4099","IMDX","BK4139","BK4555","03160","TM"],"gpt_icon":0},{"id":"2601857908","title":"Imdx Prepares for U.S. Commercial Launch of Graftassuredx as Clinical Trial Nears Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2601857908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601857908?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA9SGSJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2593490970","title":"Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593490970","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593490970?lang=en_us&edition=fundamental","pubTime":"2025-12-23 18:29","pubTimestamp":1766485751,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Insight Molecular Diagnostics' stock price is sensitive...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/news/hedge-funds-investors-control-50-of-insight-molecular-diagno","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/news/hedge-funds-investors-control-50-of-insight-molecular-diagno","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain",".IXIC","USJW.SI","NQmain","QID","TSYW.SI","USAW.SI","BK4139","PSQ","IMDX","NVIW.SI","SQQQ","TQQQ","QLD"],"gpt_icon":1},{"id":"2582039954","title":"Insight Molecular Diagnostics Reaffirms Mid-2026 Launch Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2582039954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582039954?lang=en_us&edition=fundamental","pubTime":"2025-11-12 02:10","pubTimestamp":1762884631,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on November 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLbXFvrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDIT","BK4082","IMDX"],"gpt_icon":0},{"id":"2582800427","title":"Insight Molecular Diagnostics Inc. reports $260,000 Q3 2025 revenue from laboratory services","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800427","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800427?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:12","pubTimestamp":1762809170,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc. reported revenues of $0.26 million in Q3 2025, derived from laboratory services performed at its Nashville clinical laboratory. The company remains pre-revenue in relation to kitted product sales, with no kitted product revenue recognized in the quarter. Gross profit was $0.14 million, representing a 53.5% gross margin. Research and development expenses rose 18% sequentially to $3.9 million, while sales and marketing expenses declined 5% to $1.4 million. General and administrative expenses decreased 4% to $2.5 million. The company reported a net loss of $10.9 million, or  per share. Cash, cash equivalents, and restricted cash totaled $20.2 million at quarter end. Outgoing cash flow from operations was $4.6 million, with capital expenditures of $1.1 million. The company continues to invest in FDA-compliant product development and anticipates increased expenses in Q4 2025 related to its FDA program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1p2qmX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2582638373","title":"Insight Molecular Diagnostics Inc - Q3 2025 Net Loss $10.9 Mln, or $-0.34 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2582638373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582638373?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:05","pubTimestamp":1762808701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA4DVHFK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2582203383","title":"Insight Molecular Diagnostics Inc - Graftassuredx to Be Submitted for FDA Review by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2582203383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582203383?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:05","pubTimestamp":1762808701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA4DVHFK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2582738362","title":"IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2582738362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582738362?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:05","pubTimestamp":1762808700,"startTime":"0","endTime":"0","summary":"On track to submit GraftAssureDxfor FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to-h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3185046/0/en/IMDX-Reports-Q3-2025-Results-and-Progress-Toward-2026-Commercial-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2346227817.USD","BK4588","BK4115","LU0661504455.SGD","BK4208","BK4097","ASHI","LU2065732104.USD","LU1894683348.USD","BK4139","LU1003077747.HKD","CMS","LU0949170772.SGD","LU2500361329.USD","IMDX","PRGS","LU1894683264.USD","LU0738911758.USD","BK4585","LU2637428348.USD","LU0545039389.USD","BK4075","LU0553294199.USD"],"gpt_icon":0},{"id":"2581837397","title":"Insight Molecular Diagnostics Inc  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581837397","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581837397?lang=en_us&edition=fundamental","pubTime":"2025-11-08 07:01","pubTimestamp":1762556467,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc  expected to post a loss of21cents a share - Earnings Preview Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a rise in quarterly revenue when i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ32C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IMDX","MDIT","BK4139"],"gpt_icon":0},{"id":"2575480280","title":"BRIEF-Imdx Welcomes New VP Marketing To Prepare For Commercial Transplant Assay Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2575480280","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575480280?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:18","pubTimestamp":1760386739,"startTime":"0","endTime":"0","summary":"BRIEF-Imdx Welcomes New VP Marketing To Prepare For Commercial Transplant Assay LaunchOct 13 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O:IMDX WELCOMES NEW VP MARKETING TO PREPARE FOR COMMERCI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA2QKSTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2575428057","title":"Imdx Welcomes New Vp Marketing to Prepare for Commercial Transplant Assay Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2575428057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575428057?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA2QKSTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2575280502","title":"Press Release: iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280502","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280502?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":"-- Steven Tahmooressi to lead global marketing efforts for GraftAssure. -- Brings 25 years of experience driving new product adoption across. As Vice President of Marketing, Mr. Tahmooressi will be responsible for leading transplant and oncology assay marketing, bringing more than 25 years of healthcare industry experience, including a strong history in supporting the transplantation community, ranging from U.S. sales and marketing leadership to regional and global commercialization.The mission at iMDx is to democratize access to molecular diagnostic testing -- and the company's first targeted strategic market is transplantation rejection testing, through its GraftAssure family of assays. These assays represent iMDx's initial flagship technology. The assay family includes GraftAssureCore, the company's laboratory-developed test , currently reimbursed by Medicare and performed at its CLIA-certified laboratory in Nashville. GraftAssureIQ became available for purchase in summer 2024 for r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4604","BK4099","IMDX","BK4139","BK4555","03160","TM"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}